Article in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Maria Laína SilvaDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0000-0002-6306-6854
Francisco Eilton Sousa LopesDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0000-0003-3957-8494
Paulo Henrique Peixoto SoaresDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0009-0007-8324-6194
Lua SilvaDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0009-0008-6786-4360
Pedro Paulo Rodrigues ColaresDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0009-0005-2992-3065
Bruno Nascimento da SilvaDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0000-0002-4103-9863
Pedro Filho Noronha SouzaLaboratory of Bioinformatics Applied to Health at the Medicine Research and Development Center, Federal University of Ceará, Fortaleza, Brazil.ORCID 0000-0003-2524-4434
Raquel Carvalho MontenegroLaboratory of Bioinformatics Applied to Health at the Medicine Research and Development Center, Federal University of Ceará, Fortaleza, Brazil.ORCID 0000-0002-3861-293X
Débora de Souza Collares Maia Castelo-BrancoDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0000-0002-6045-2354
Esteban Nicolás LorenzónHealth Sciences Institute, Federal University of Jatai, Jataí, Brazil.ORCID 0000-0002-1645-8564
Eduardo Maffud CilliDepartment of Biochemistry and Organic Chemistry, Estadual University of São Paulo, Araraquara, Brazil.ORCID 0000-0002-4767-0904
Victor Alves CarneiroLaboratory of Biofilms and Antimicrobial Agents (LaBAM/NUBEM), INTA University Center - UNINTA, Sobral, Brazil.ORCID 0000-0003-0116-0957
Rossana de Aguiar CordeiroDepartment of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID 0000-0001-8386-2180
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
introduction
objectiveThis study aimed to evaluate the antifungal potential of Aurein 1.2 (Au) and two modified analogs, K-aurein (K-au) and D-aurein (D-au), containing an additional lysine or aspartic acid residue, respectively, at the N-terminal of the native peptide. MATERIALS &
methodsTo this, antifungal activity, time of action by time-kill curve, ergosterol-binding analysis
conclusionThese findings highlight Au-derived peptides as promising molecules against
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Aurein 1.2 analogues as promising agents against · full record | OpenQuestion